Saturday, 31 October 2026European Markets

ORDINA And 3 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - carmila (carm.pa), melhus sparebank (melg.ol), ordina (ordi.as) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio at the moment. the payout ratio in itself isn't a guarantee of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

when investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. carmila (carm.pa)

172.06% payout ratio

the third-largest listed owner of retail property in europe, carmila was founded by carrefour and institutional investors to enhance the value of shopping centres adjoining carrefour hypermarkets in france, spain and italy. at 30 june 2023, its portfolio was valued at €6.0 billion and made up of 202 shopping centres, with leading positions in their catchment areas. carmila is listed on euronext-paris compartment a under the symbol carm. it benefits from the tax regime for french real estate investment trusts ("siic"). carmila has been a member of the sbf 120 since 20 june 2022.

earnings per share

as for profitability, carmila has a trailing twelve months eps of €1.52.

pe ratio

carmila has a trailing twelve months price to earnings ratio of 9.7. meaning, the purchaser of the share is investing €9.7 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.89%.

revenue growth

year-on-year quarterly revenue growth grew by 5.6%, now sitting on 476.07m for the twelve trailing months.

volume

today's last reported volume for carmila is 3799 which is 91.71% below its average volume of 45865.

more news about carmila.

2. melhus sparebank (melg.ol)

66.91% payout ratio

melhus sparebank, a savings bank, provides various banking products and services to companies, agriculture customers, and private individuals in norway. the company offers savings accounts; construction and business loans; bank guarantee, overdraft, and leasing services; and credit and bank cards. it also provides various insurance products for liability, health, personnel, occupational injury, travel, accident, business, store, data attack, property damage, craftsman, homeowners, office, vehicle, and farms; savings and pension products; payment services; and online and mobile banking services. the company operates through branch offices in central trondheim, heimdal, ler, and korsvegen. melhus sparebank was founded in 1840 and is headquartered in melhus, norway.

earnings per share

as for profitability, melhus sparebank has a trailing twelve months eps of kr16.45.

pe ratio

melhus sparebank has a trailing twelve months price to earnings ratio of 9.42. meaning, the purchaser of the share is investing kr9.42 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

yearly top and bottom value

melhus sparebank's stock is valued at kr155.00 at 11:10 est, way below its 52-week high of kr177.00 and higher than its 52-week low of kr142.00.

growth estimates quarters

the company's growth estimates for the current quarter and the next is 40.1% and 18.8%, respectively.

volume

today's last reported volume for melhus sparebank is 210 which is 44% below its average volume of 375.

revenue growth

year-on-year quarterly revenue growth grew by 52.6%, now sitting on 293.36m for the twelve trailing months.

more news about melhus sparebank.

3. ordina (ordi.as)

60.77% payout ratio

ordina n.v. provides it services in the netherlands, belgium, and luxembourg. it engages in the development and implementation of software solutions, as well as designing and managing it landscapes. the company also provides consulting, technology, and outsourcing services. it serves customers in public, financial services, and industry sectors. ordina n.v. was incorporated in 1973 and is headquartered in nieuwegein, the netherlands. as of september 26, 2023, ordina n.v. operates as subsidiary of sopra steria group sa.

earnings per share

as for profitability, ordina has a trailing twelve months eps of €0.24.

pe ratio

ordina has a trailing twelve months price to earnings ratio of 23.75. meaning, the purchaser of the share is investing €23.75 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.64%.

more news about ordina.

4. coca-colaeuropacif (ccep.as)

48.51% payout ratio

coca-cola europacific partners plc, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready to drink beverages. it offers flavours, mixers, and energy drinks; soft drinks, waters, enhanced water, and isotonic drinks; and ready-to-drink tea and coffee, juices, and other drinks. the company provides its products under the coca-cola, diet coke, coca-cola zero sugar, fanta, sprite, monster energy, coca-cola energy, relentless, nalu, urge, burn, kuli, reign, powerade, appletiser, schweppes, finley, mezzo mix, royal bliss, lift, vio schorle, coca-cola signature mixers, nordic mist, smartwater, chaudfontaine, aquarius, vilas del turbon, bonaqua, apollinaris, krystal, honest, costa coffee, fuzetea, chaqwa, nestea, capri-sun, oasis, minute maid, mer, and tropico brands. in addition, it engages in the bottling and other operations. the company was formerly known as coca-cola european partners plc and changed its name to coca-cola europacific partners plc in may 2021. coca-cola europacific partners plc was founded in 1904 and is based in uxbridge, the united kingdom.

earnings per share

as for profitability, coca-colaeuropacif has a trailing twelve months eps of €3.69.

pe ratio

coca-colaeuropacif has a trailing twelve months price to earnings ratio of 14.96. meaning, the purchaser of the share is investing €14.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.88%.

more news about coca-colaeuropacif.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1's stock is considered to be overbought (>=80).

earnings before interest, taxes, depreciation, and amortization

1's ebitda is 1.

volatility

1's last week, last month's, and last quarter's current intraday variation average was 1.00%, 1.00%, and 1.00%.

1's highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).

dividend yield

according to morningstar, inc., the next dividend payment is on jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.

more news about 1.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com